Data on a new treatment approach utilizing bispecific monoclonal antibodies targetting B-cell maturation antigen (BCMA) were recently published, yielding very encouraging results in the setting of relapsed and/or refractory multiple myeloma (RRMM). How to safely and effectively deliver this treatment to patients and where it fits in the RRMM treatment paradigm are important questions for the future.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705–716 (2021).
Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 398, 314–324 (2021).
Moreau, P. et al. Teclistamab in elapsed or refractory multiple myeloma. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2203478 (2022).
Lonial, S. et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 21, 207–222 (2020).
Chari, A. et al. Oral selinexor-dexamethasone for triple-class efractory multiple myeloma. N. Engl. J. Med. 381, 727–738 (2019).
Samur, M. K. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat. Commun. 12, 868 (2021).
Da Vià, M. C. et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat. Med. 27, 616–619 (2021).
Lesokhin, A. M. et al. Initial safety results for MagnetisMM-3: a phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM). J. Clin. Oncol. 16 (suppl.), 8006 (2022).
Trudel, S. et al. Cevostamab monotherapy continues to show clinically meaningful activity and anageable safety in patients with heavily pre-treated relapsed/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study. Blood 138 (Suppl. 1), 157 (2021).
Berdeja, J. G. et al. Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM). J. Clin. Oncol. 39 (suppl. 15), 8008 (2021).
Acknowledgements
S.L. receives support from the Paula and Rodger Riney Foundation and holds the Anne and Bernard Gray Family Chair in Cancer.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
K.P. has acted as a consultant for Arcellx, BMS, Caribou Biosciences, Celgene, Cellectis, Janssen, Karyopharm, Legend Biotech, Merck, Nektar, Pfizer, Takeda. S.L. has acted as a consultant for ABBVIE, Amgen, BMS, Celgene, GSK, Janssen, Novartis, Takeda, is a member of the board of directors and holds stock in TG therapeutics.
Rights and permissions
About this article
Cite this article
Patel, K., Lonial, S. When an embarrassment of riches isn’t enough. Nat Rev Clin Oncol 19, 617–618 (2022). https://doi.org/10.1038/s41571-022-00670-w
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41571-022-00670-w
